SCHEMBL24252689

SCHEMBL24252689

COc1ccc(B(O)O)c(F)c1-c1ccc2c(N)nnc(C)c2c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 2/20 0.36
MAPT P10636 2/20 0.34
LMNA P02545 1/20 0.34
SMN1; SMN2 Q16637 3/20 0.32
HSD17B10 Q99714 3/20 0.31
FYN P06241 2/20 0.31
TSHR P16473 2/20 0.31
CYP3A4 P08684 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
MEN1 O00255 3/20 0.30
KMT2A Q03164 3/20 0.30
RAB9A P51151 2/20 0.30
NPC1 O15118 1/20 0.30
TNF P01375 1/20 0.30
TP53 P04637 1/20 0.30
GAA P10253 1/20 0.30
MAPK1 P28482 1/20 0.30
HTT P42858 1/20 0.30
CCR6 P51684 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL25240804 0.95 ERN1 (0.33) ALDH1A1KDM4EMAPTLMNASMN1; SMN2
Formic Acid SCHEMBL30451252 0.95 ERN1 (0.33) ALDH1A1KDM4EMAPTLMNASMN1; SMN2
SCHEMBL26771120 0.93 KDM4E (0.34) ALDH1A1KDM4EMAPTLMNASMN1; SMN2
SCHEMBL25240802 0.88 ERN1 (0.34) ALDH1A1KDM4EMAPTLMNA
SCHEMBL24252282 0.82 KIF11 (0.30)
SCHEMBL30451530 0.80 FYN (0.34) KDM4EFYNTDP1DHFR
SCHEMBL24252645 0.80 FYN (0.34) KDM4EFYNTDP1DHFR
Formic Acid SCHEMBL30452072 0.78
Formic Acid SCHEMBL25259327 0.78
SCHEMBL24252646 0.77 DHFR (0.36) ALDH1A1HSD17B10FYNTSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 ALDH1A1 653/4885KDM4E 3923/4885MAPT 1152/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 ALDH1A1 653/4885KDM4E 3923/4885MAPT 1152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.